^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastrointestinal Cancer

    23h
    MAGMAP: Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Ferronova Pty Ltd | Recruiting --> Active, not recruiting | Trial completion date: Feb 2029 --> May 2029 | Trial primary completion date: Feb 2026 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    24h
    A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis (clinicaltrials.gov)
    P=N/A, N=180, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Sep 2029 --> Dec 2025 | Trial primary completion date: Sep 2027 --> Sep 2025 | Enrolling by invitation --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    1d
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    4d
    Harnessing Isorhamnetin for Gastrointestinal Cancers: Molecular Mechanisms and Therapeutic Potential. (PubMed, J Biochem Mol Toxicol)
    Recent emerging nanotechnological approaches aim to address these challenges by enhancing their bioavailability and targeted delivery. This manuscript emphasizes the anticancer potential of isorhamnetin in GI malignancies, with a particular focus on its molecular mechanisms of action, chemopreventive properties, and recent progress in nanoformulation-based strategies.
    Review • Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    4d
    A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (clinicaltrials.gov)
    P3, N=450, Recruiting, GlaxoSmithKline
    Trial initiation date
    |
    imatinib • sunitinib • velzatinib (GSK6042981)
    4d
    Anti-cancer effect of a novel photodynamic therapy using glucose-linked chlorin e6 conjugated trastuzumab for HER2-positive gastrointestinal cancers. (PubMed, PLoS One)
    Evaluation of cell death using the WST-8 assay also demonstrated a significantly higher cytotoxic effect of G-Ce6-trastuzumab in HER2-high-expression cells compared with conventional PS G-Ce6. Thereby, G-Ce6-trastuzumab may be an excellent novel PS for PDT because of its strong selectivity for HER2-high-expression cells.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 expression • HER-2 underexpression
    |
    Herceptin (trastuzumab)
    5d
    NCI-2020-04427: Cancer Genetic Testing in Ethnic Populations (clinicaltrials.gov)
    P=N/A, N=1800, Recruiting, Mayo Clinic | Trial completion date: Oct 2026 --> Oct 2028 | Trial primary completion date: Oct 2026 --> Oct 2028
    Trial completion date • Trial primary completion date
    5d
    LITESPARK-015: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) (clinicaltrials.gov)
    P2, N=322, Recruiting, Merck Sharp & Dohme LLC | N=171 --> 322
    Enrollment change
    |
    Welireg (belzutifan)
    6d
    Circulating fatty acids and risk of gastrointestinal cancer in the UK Biobank. (PubMed, Front Nutr)
    Circulating FAs are closely associated with GI cancer risk, aiding in the screening of high-risk populations. Moreover, targeted control of FAs levels may help reduce the risk of GI cancer occurrence in populations.
    Journal
    |
    FAS (Fas cell surface death receptor)
    6d
    Frontiers in Gut Health: The Emerging Role of Berries in Microbiota Modulation and Gastrointestinal Diseases. (PubMed, Nutr Rev)
    Berries may also exert chemopreventive actions in GI cancers by influencing Wnt signaling, COX-2 expression, and DNA methylation. Although in vitro, in vivo, and early-phase clinical studies provide encouraging evidence, larger berry-specific human trials are required to confirm these effects and clarify mechanisms for personalized interventions.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    6d
    Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors (clinicaltrials.gov)
    P2, N=189, Completed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Herceptin (trastuzumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    6d
    ESCAPE: Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients (clinicaltrials.gov)
    P=N/A, N=66, Recruiting, Erasmus Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • capecitabine